NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality – First Clinical Site Contracted
- Tuesday, January 3, 2023, 7:03
- Finance
- Add a comment
First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a Special Protocol Assessment (“SPA”) for this trial helping to mitigate risks and accelerate the…
About the Author
adminasapcorp has written 39584 stories on this site.